| Heart disease and stroke statistics—2016 update: a report from the American Heart Association D Mozaffarian, EJ Benjamin, AS Go, DK Arnett, MJ Blaha, M Cushman, ... circulation 133 (4), e38-e360, 2016 | 74758* | 2016 |
| Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes B Zinman, C Wanner, JM Lachin, D Fitchett, E Bluhmki, S Hantel, ... New england journal of medicine 373 (22), 2117-2128, 2015 | 12147 | 2015 |
| 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with … FLJ Visseren, F Mach, YM Smulders, D Carballo, KC Koskinas, M Bäck, ... European journal of preventive cardiology 29 (1), 5-115, 2022 | 4103 | 2022 |
| Empagliflozin and progression of kidney disease in type 2 diabetes C Wanner, SE Inzucchi, JM Lachin, D Fitchett, M von Eynatten, ... New England Journal of Medicine 375 (4), 323-334, 2016 | 3849 | 2016 |
| Cardiovascular and renal outcomes with empagliflozin in heart failure M Packer, SD Anker, J Butler, G Filippatos, SJ Pocock, P Carson, ... New England Journal of Medicine 383 (15), 1413-1424, 2020 | 3831 | 2020 |
| Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis C Wanner, V Krane, W März, M Olschewski, JFE Mann, G Ruf, E Ritz New England Journal of Medicine 353 (3), 238-248, 2005 | 3008 | 2005 |
| The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo … C Baigent, MJ Landray, C Reith, J Emberson, DC Wheeler, C Tomson, ... The Lancet 377 (9784), 2181-2192, 2011 | 2927 | 2011 |
| A proposed nomenclature and diagnostic criteria for protein–energy wasting in acute and chronic kidney disease D Fouque, K Kalantar-Zadeh, J Kopple, N Cano, P Chauveau, L Cuppari, ... Kidney international 73 (4), 391-398, 2008 | 2364 | 2008 |
| Inflammation enhances cardiovascular risk and mortality in hemodialysis patients J Zimmermann, S Herrlinger, A Pruy, T Metzger, C Wanner Kidney international 55 (2), 648-658, 1999 | 2193 | 1999 |
| Review on uremic toxins: classification, concentration, and interindividual variability R Vanholder, R De Smet, G Glorieux, A Argilés, U Baurmeister, P Brunet, ... Kidney international 63 (5), 1934-1943, 2003 | 1951 | 2003 |
| Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study M Ketteler, P Bongartz, R Westenfeld, JE Wildberger, AH Mahnken, ... The Lancet 361 (9360), 827-833, 2003 | 1235 | 2003 |
| EBPG guideline on nutrition D Fouque, M Vennegoor, P Ter Wee, C Wanner, A Basci, B Canaud, ... Nephrology Dialysis Transplantation 22 (suppl_2), ii45-ii87, 2007 | 1092 | 2007 |
| EBPG on vascular access J Tordoir, B Canaud, P Haage, K Konner, A Basci, D Fouque, J Kooman, ... Nephrology Dialysis Transplantation 22 (suppl_2), ii88-ii117, 2007 | 1090 | 2007 |
| Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial J Rosenstock, V Perkovic, OE Johansen, ME Cooper, SE Kahn, N Marx, ... Jama 321 (1), 69-79, 2019 | 1075 | 2019 |
| Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial D Fitchett, B Zinman, C Wanner, JM Lachin, S Hantel, A Salsali, ... European heart journal 37 (19), 1526-1534, 2016 | 1074 | 2016 |
| Oxidative stress in end‐stage renal disease: an emerging threat to patient outcome F Locatelli, B Canaud, KU Eckardt, P Stenvinkel, C Wanner, C Zoccali Nephrology Dialysis Transplantation 18 (7), 1272-1280, 2003 | 1045 | 2003 |
| Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease D De Zeeuw, T Akizawa, P Audhya, GL Bakris, M Chin, H Christ-Schmidt, ... New England Journal of Medicine 369 (26), 2492-2503, 2013 | 1032 | 2013 |
| Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM) JJ Carrero, P Stenvinkel, L Cuppari, TA Ikizler, K Kalantar-Zadeh, ... Journal of renal nutrition 23 (2), 77-90, 2013 | 1023 | 2013 |
| The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials CT Trialists The Lancet 380 (9841), 581-590, 2012 | 1009 | 2012 |
| Chronic kidney disease P Romagnani, G Remuzzi, R Glassock, A Levin, KJ Jager, M Tonelli, ... Nature reviews Disease primers 3 (1), 1-24, 2017 | 987 | 2017 |
